Semaglutide reduced the risk of kidney disease worsening ... This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects ...

Novo Nordisk has reported headline results from the FLOW trial, where its semaglutide demonstrated a 24% reduction in kidney disease progression and mortality. The parallel-group, superiority ...